ExodusPoint Capital Management LP Grows Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

ExodusPoint Capital Management LP increased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 232.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 212,824 shares of the company's stock after acquiring an additional 148,842 shares during the quarter. ExodusPoint Capital Management LP owned approximately 0.46% of Pacira BioSciences worth $4,010,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Verition Fund Management LLC acquired a new position in Pacira BioSciences in the 3rd quarter valued at about $493,000. Centiva Capital LP acquired a new position in Pacira BioSciences in the third quarter valued at approximately $398,000. State Street Corp grew its position in Pacira BioSciences by 5.8% in the third quarter. State Street Corp now owns 2,014,012 shares of the company's stock worth $30,311,000 after acquiring an additional 110,162 shares during the period. Charles Schwab Investment Management Inc. grew its position in Pacira BioSciences by 16.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock worth $9,462,000 after acquiring an additional 70,307 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after acquiring an additional 2,749 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Analysts Set New Price Targets

PCRX has been the subject of a number of research analyst reports. HC Wainwright increased their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and increased their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada reiterated a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays increased their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Pacira BioSciences in a research report on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $26.67.

Pacira BioSciences Stock Up 3.7 %

Pacira BioSciences stock traded up $0.87 during mid-day trading on Friday, reaching $24.56. 605,564 shares of the company's stock were exchanged, compared to its average volume of 969,947. The company has a fifty day moving average of $24.74 and a 200-day moving average of $20.81. The company has a market cap of $1.14 billion, a P/E ratio of -12.10 and a beta of 0.71. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.